The AHA recently released a scientific statement surrounding the management of drug-induced arrhythmias including discontinuation of the offending medication and following treatment guidelines for the specific arrhythmia.

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association

Circulation

New England Journal of Medicine

In a recently released, double-blind trial of 3,730 patients those receiving empagliflozin had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.